Phase 1/2 study of topical submicron particle paclitaxel for cutaneous metastases of breast cancer

Mario E Lacouture, Shari B Goldfarb, Alina Markova, Sant P Chawla, Karan Dewnani, Marc Iacobucci, Julie E Lang, Mario E Lacouture, Shari B Goldfarb, Alina Markova, Sant P Chawla, Karan Dewnani, Marc Iacobucci, Julie E Lang

Abstract

Purpose: This Phase 1/2 study evaluated safety and efficacy of a topical submicron particle paclitaxel (SPP) in an anhydrous ointment base (SOR007), primarily in breast cancer patients with cutaneous metastases (CM).

Methods: One of three concentrations of SOR007 SPP (0.15%, 1.0%, or 2.0%) was applied twice daily over an area of 50 cm2 under a 3 + 3 phase 1 design for up to 28 days, with the option for expansion to an additional 28 days at the highest dose under a Phase 2a once safety was established. Efficacy was analyzed by lesion measurements and photographs to determine overall response rate (ORR), complete response (CR), and progression free survival by day 28 or 56.

Results: Twenty-three subjects were enrolled, 21 with cutaneous metastases of breast cancer (CMOBC). Four subjects received SOR007 0.15% for a median of 28 days (range = 17-29), three at a dose of 1.0% for a median of 28 days (range = 6-29), and sixteen at 2.0% for a median of 55 days (range = 6-60). All doses were well tolerated, and 19 subjects were evaluable for efficacy. At day 28 across all dose levels, 16% (95% CI 3.4 to 39.6%) of subjects achieved an ORR and another 63% (95% CI 34.9-96.8%) had stable disease (SD). The proportion of patients being progression free at 28 days across all treatments was 79% (95 CI 54-94%).

Conclusion: Application of SOR007 0.15%, 1.0%, and 2.0% to CM was safe and well tolerated with some reduction in lesion pain, and minimal systemic absorption of paclitaxel. Lesion stabilization was observed in most subjects over the study period. A randomized, placebo-controlled trial to confirm these findings is warranted.

Gov identifier: NCT03101358.

Keywords: Breast cancer; Clinical trial; Cutaneous metastases; Paclitaxel; SOR007; Submicron particle paclitaxel.

Conflict of interest statement

The following authors report holding a consultant/advisory role, having stock ownership, or receiving research funding from NanOlogy; M.E.L., S.B.G., A.M., S.P.C., K.D., M.I., and J.E.L.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Best overall response to SOR007 in 36 cutaneous lesions from 19 patients (RECIST 1.1)
Fig. 2
Fig. 2
Example of CMOBC lesion prior to treatment (a) with SOR007 2.0% and at end of study (b) recorded as complete response

References

    1. Spratt DE, Gordon Spratt EA, Wu S, DeRosa A, Lee NY, Lacouture ME, Barker CA. Efficacy of skin-directed therapy for cutaneous metastases from advanced cancer: a meta-analysis. J Clin Oncol. 2014;32:3144–3155. doi: 10.1200/JCO.2014.55.4634.
    1. Alcaraz I, Cerroni L, Rütten A, Kutzner H, Requena L. Cutaneous metastases from internal malignancies: a clinicopathologic and immunohistochemical review. Am J Dermatopathol. 2012;34:347–393. doi: 10.1097/DAD.0b013e31823069cf.
    1. Krathen RA, Orengo IF, Rosen T. Cutaneous metastasis: a meta-analysis of data. South Med J. 2003;96:164–167. doi: 10.1097/01.SMJ.0000053676.73249.E5.
    1. Lookingbill DP, Spangler N, Helm KF. Cutaneous metastases in patients with metastatic carcinoma: a retrospective study of 4020 patients. J Am Acad Dermatol. 1993;29(2 Pt 1):228–236. doi: 10.1016/0190-9622(93)70173-Q.
    1. Virgen CA, Barker CA, Lacouture ME. The microbial flora of clinically infected cutaneous metastases: a retrospective study. Clin Exp Dermatol. 2020;45:722–726. doi: 10.1111/ced.14241.
    1. Wong CYB, Helm MA, Kalb RE, Helm TN, Zeitouni NC. The presentation, pathology, and current management strategies of cutaneous metastases. N Am J Med Sci. 2013;5:499–504. doi: 10.4103/1947-2714.118918.
    1. Leonard R, Hardy J, van Tienhoven G, et al. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. J Clin Oncol. 2001;19:4150–4159. doi: 10.1200/JCO.2001.19.21.4150.
    1. Kalmykow B, Walker S. Cutaneous metastases in breast cancer. Clin J Oncol Nurs. 2011;15:99–101. doi: 10.1188/11.CJON.99-101.
    1. Saeed S, Keehn CA, Morgan MB. Cutaneous metastasis: a clinical, pathological, and immunohistochemical appraisal. J Cutan Pathol. 2004;31:419–430. doi: 10.1111/j.0303-6987.2004.00207.x.
    1. Bastard DP, Bollea-Garlatti ML, Belatti A, Puga MC, Hernández MN, Mazzuoccolo LD. Cutaneous metastases from breast cancer: an 8-year review of cases at a tertiary care hospital. Actas Dermosifiliogr. 2019;110:206–211. doi: 10.1016/j.ad.2018.12.004.
    1. Campana LG, Clover AJP, Valpione S, Quaglino P, Gehl J, Kunte C, Snoj M, Cemazar M, Rossi CR, Miklavcic D, Sersa G. Recommendations for improving the quality of reporting clinical electrochemotherapy studies based on qualitative systematic review. Radiol Oncol. 2016;50:1–13. doi: 10.1515/raon-2016-0006.
    1. Haefeli M, Elfering A. Pain assessment. Eur Spine J. 2006;15(Suppl 1):S17–S2. doi: 10.1007/s00586-005-1044-x.
    1. Ágoston D, Baltás E, Ócsai H, Rátkai S, Lázár PG, et al. Evaluation of calcium electroporation for the treatment of cutaneous metastases: a double blinded randomised controlled phase II trial. Cancers. 2020;12:179. doi: 10.3390/cancers12010179.
    1. Baltezor M, Farthing J, Sittenauer J, Espinosa J, Campbell S, McClorey M, Fischer JK, Williams MD, Clapp GE (2017) Taxane particles and their use. U.S. Patent 9,814,685. . Accessed 26 July 2021
    1. Verco S, Maulhardt H, Baltezor M, Williams E, Iacobucci M, et al. Local administration of submicron particle paclitaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects without local or systemic toxicity: preclinical and clinical studies. Drug Deliv Transl Res. 2021;11:1806–1817. doi: 10.1007/s13346-020-00868-4.
    1. Sideras K, Zahasky KM, Kaur JS. Response of cutaneous metastases from breast cancer to capecitabine. Clin Med Oncol. 2008;2:415–418.
    1. Cabula C, Campana LG, Grilz G, Galuppo S, Bussone R, et al. Electrochemotherapy in the treatment of cutaneous metastases from breast cancer: a multicenter cohort analysis. Ann Surg Oncol. 2015;22(Suppl 3):S442–S450. doi: 10.1245/s10434-015-4779-6.
    1. Fernández-Antón Martínez MC, Parra-Blanco V, Avilés Izquierdo JA, Suárez Fernández RM. Cutaneous metastases of internal tumors. Actas Dermosifiliogr. 2013;104:841–853. doi: 10.1016/j.ad.2012.06.005.
    1. Bourke MG, Salwa SP, Sadadcharm, Whelan MC, Forde PF, et al. Effective treatment of intractable cutaneous metastases of breast cancer with electrochemotherapy: ten-year audit of single center experience. Breast Cancer Res Treat. 2017;161:289–297. doi: 10.1007/s10549-016-4046-y.
    1. Data on file. NanOlogy LLC. Report #: DR2015.006. Kisak E (2015) Report for measurements of skin penetration from prototype paclitaxel formulations. May 18, 2015
    1. Study of SOR007 Ointment for actinic keratosis (NCT03083470). Study results. (). Accessed 15 Sep 2021
    1. Goto H, Omodaka T, Yanagisawa H, Yoshikawa S, Yoshida Y, et al. Palliative surgical treatment for cutaneous metastatic tumor is a valid option for improvement of quality of life. J Dermatol. 2016;43:95–98. doi: 10.1111/1346-8138.12983.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever